| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/01/2010 | EP2222710A1 Recombinant rsv antigens |
| 09/01/2010 | EP2222709A2 Antigen-binding constructs |
| 09/01/2010 | EP2222706A1 Antibodies against human nkg2d and uses thereof |
| 09/01/2010 | EP2222705A1 Antigen binding proteins |
| 09/01/2010 | EP2222704A1 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis |
| 09/01/2010 | EP2222702A1 Human monoclonal nicotine specific antibodies |
| 09/01/2010 | EP2222701A2 Antibodies against influenza virus and methods of use thereof |
| 09/01/2010 | EP2222344A2 Dendritic cell vaccine compositions and uses of same |
| 09/01/2010 | EP2222337A2 Allergens and allergoids from bee venom |
| 09/01/2010 | EP2222331A2 An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases |
| 09/01/2010 | EP1833508B1 Porcine reproductive and respiratory syndrome virus strains and compositions |
| 09/01/2010 | EP1613347B1 Humanized antibodies that recognize beta amyloid peptide |
| 09/01/2010 | EP1606409B1 Nogo receptor binding protein |
| 09/01/2010 | EP1427815B1 Methods for the industrial production of vaccines |
| 09/01/2010 | EP1337558B1 A "bach" g protein coupled receptor polypeptide and polynucleotide encoding this receptor |
| 09/01/2010 | EP1207905B1 Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents |
| 09/01/2010 | CN1836729B Target antibody compound for killing tumour cell and its preparation method |
| 09/01/2010 | CN101821627A Immunogenic streptococcus proteins |
| 09/01/2010 | CN101821623A Materials and methods for sperm sex selection |
| 09/01/2010 | CN101821403A Cell for use in the production of exogenous protein, and production process using the cell |
| 09/01/2010 | CN101821392A RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles |
| 09/01/2010 | CN101821292A Combination therapy with type i and type ii anti-cd20 antibodies |
| 09/01/2010 | CN101821290A Influenza virus haemagglutinin-specific monoclonal antibodies |
| 09/01/2010 | CN101821284A Novel genes and proteins of brachyspira hyodysenteriac and uses thereof |
| 09/01/2010 | CN101820913A Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor |
| 09/01/2010 | CN101820912A Antibody formulations |
| 09/01/2010 | CN101820911A Humanized antibodies to amyloid beta |
| 09/01/2010 | CN101820910A Antibodies binding to an intracellular prl-1 or prl-3 polypeptide |
| 09/01/2010 | CN101820909A Methods of enhancing adjuvanticity of vaccine compositions |
| 09/01/2010 | CN101820908A Immune stimulatory oligonucleotide analogs containing modified sugar moieties |
| 09/01/2010 | CN101820907A Peptide with multiple epitopes |
| 09/01/2010 | CN101820906A Cytomegalovirus vaccines and methods of production |
| 09/01/2010 | CN101820905A Recombinant koi herpesvirus (KHV) or cyprinid herpesvirus 3 (CyHV-3) and vaccine for the prevention of disease caused by KHV/CyHV-3 in cyprinus carpio carpio or cyprinus carpio koi |
| 09/01/2010 | CN101820904A Method of eliciting an immune response against pandemic influenza virus |
| 09/01/2010 | CN101820903A Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods |
| 09/01/2010 | CN101820902A Live attenuated mycoplasma strains |
| 09/01/2010 | CN101820901A Vaccines |
| 09/01/2010 | CN101820900A Composition for treating prostate cancer (PCa) |
| 09/01/2010 | CN101820899A Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| 09/01/2010 | CN101820898A Functional humanization of complementarity determining regions (cdrs) |
| 09/01/2010 | CN101820892A Treatment regime for proliferative disorders |
| 09/01/2010 | CN101820870A Uses of trientine and penicillamine as countermeasures to metal contamination |
| 09/01/2010 | CN101818185A Purification process for bacterial cytolysin |
| 09/01/2010 | CN101818163A Recombined adenovirus expressing Asia-1 foot-and-mouth disease virus VLP (Virus-like Particles) and application thereof |
| 09/01/2010 | CN101818162A Molecular design of IBDV (Infectious Bursal Disease Virus) antigen epitope and HBcAg (Hepatitis B Core Antigen) chimeric gene |
| 09/01/2010 | CN101818133A VSIG4 (V-set and Ig domain containing 4) and IGRP (glucose-6-phosphatase catalytic subunit-related protein) dual-gene coexpression recombinant adenovirus as well as preparation method and application thereof |
| 09/01/2010 | CN101818132A Construction of chimeric rabies strain rLEP333Q-L(H) and research on biological function thereof |
| 09/01/2010 | CN101818131A Production method for influenza virus vaccines |
| 09/01/2010 | CN101818130A gG and TK gene-deleted recombinant infectious bovine rhinotracheitis virus and application |
| 09/01/2010 | CN101816799A Gene vaccine of sperm-specific cationic channel protein CatSper1 and preparation method thereof |
| 09/01/2010 | CN101816798A Gene vaccine of sperm-specific protein Ropporin and preparation method thereof |
| 09/01/2010 | CN101816792A Combinations comprising epothilones and pharmaceutical uses thereof |
| 09/01/2010 | CN101816790A Spray for treating radioactive xerostomia and preparation method thereof |
| 09/01/2010 | CN101816789A Lyophilized viper antivenin and preparation method thereof |
| 09/01/2010 | CN101816788A Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 09/01/2010 | CN101816787A An allergen dosage form |
| 09/01/2010 | CN101816786A Inactivated hepatitis A vaccine and preparation method thereof |
| 09/01/2010 | CN101816785A Preparation method and product of H9N2 subtype avian influenza inactivated vaccine |
| 09/01/2010 | CN101816784A Immunoprotective subunit vaccine, preparation method thereof and application method thereof |
| 09/01/2010 | CN101816783A Recombinant Mycobacterium smegmatis vaccine expressing HBHA-IL-12 fusion protein |
| 09/01/2010 | CN101816631A Liposome preparation for tumor therapeutic vaccine and preparation method thereof |
| 09/01/2010 | CN101186648B Pseudomonas aeruginosa resisting Fab' fragment |
| 08/31/2010 | USRE41595 Application of hydrophobic interaction chromatography combination chromatography to the purification of antibody molecule proteins, for purifying monomeric IgG antibody from a mixture of monomeric IgG antibody and at least one of immunoglobulin aggregates; biological substance purification |
| 08/31/2010 | US7786288 A binding site of the cystosolic protein cyclophilin A on human immunodeficiency virus capsid protein, which may be expressed by a recombinant viral, bacterial or yeast carrier; may be treated with neuraminidase or trypsin to remove sialic acid; immune stimulant such as teichoic acid or zymosan |
| 08/31/2010 | US7786286 Microorganismal, outer-membrane, enzymatic polypeptide for use in developing vaccine for prevention and treatment of nesserial infection |
| 08/31/2010 | US7786285 Nucleic acid, expression vectors and host cells for synthetic genes, chosen from a gram negative bacteria, yeast, or mammalian cell; zinc-endopeptidases that specifically cleave the synaptosomal proteins, SNAP-25, VAMP, or syntaxin at discrete sites |
| 08/31/2010 | US7786279 Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection |
| 08/31/2010 | US7786278 improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer; carcinoembryonic antigen (CEA) |
| 08/31/2010 | US7786273 free of a denaturing reagent and comprising of an antibody that binds to a respiratory syncytial virus (RSV) antigen, a human metapneumovirus (hMPV) antigen, integrin alpha v beta 3, CD2, CD19, an Eph receptor, or to IL-9 |
| 08/31/2010 | US7786269 The antibodies or fragments specifically bind to an extracellular epitope of an Epstein Barr Virus latent membrane protein; anticarcinogenic agents; cancer vaccines |
| 08/31/2010 | US7786268 Anti-IP-10 antibodies and methods of use thereof |
| 08/31/2010 | US7786267 Multivariable antigens complexed with targeting humanized monoclonal antibody |
| 08/31/2010 | US7786266 Desmocollin 2 (DSC2) specific immunoglobulin for use in prevention and treatment of cell proliferative disorders |
| 08/31/2010 | US7786264 Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof |
| 08/31/2010 | US7786260 immunogenic; treating or preventing Helicobacter infection in a mammalian host; gastroduodenal disease |
| 08/31/2010 | US7786096 Inhibition of antigen presentation with poorly catabolized polymers |
| 08/31/2010 | US7786094 Use of beta-glucans against biological warfare weapons and pathogens including anthrax |
| 08/31/2010 | US7785903 Variable domain library and uses |
| 08/31/2010 | US7785886 Contacting ABC1-expressing cells with a composition containing test compound and measuring biological activity by determining the level of efflux of labeled substrate ; use in treating cardiovascular disease |
| 08/31/2010 | US7785875 Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same |
| 08/31/2010 | US7785873 Antigen arrays for treatment of bone disease |
| 08/31/2010 | US7785856 therapeutic fusion protein comprising amino acid residues 70-952 of human acid alpha-glucosidase (GAA) and a peptide tag; permits M6P-independent targeting of human GAA or GAA-like enzymes to patient lysosomes |
| 08/31/2010 | US7785841 Methods for the early diagnosis of ovarian cancer |
| 08/31/2010 | US7785829 polynucleotide encoding a soluble polypeptide; for decreasing inhibition of axonal growth of a central nervous system neuron; neurological diseases, disorders and injuries such as spinal cord injury |
| 08/31/2010 | US7785819 Diagnosis of autoimmune disease; generate solid support, incubate with fluid sample, detect preferential antigens, compare to control, evaluate for autoimmune diseases |
| 08/31/2010 | US7785817 Using caudal-1 gene (CDX-1) as diagnostic indicator of stomach or esophageal cancer; immunodiagnostics |
| 08/31/2010 | US7785811 Using lutetium label probes to detect tumor secreted antigens and diagnose/prognose cell proliferative disorders |
| 08/31/2010 | US7785804 Mammalian CX3C chemokine antibodies |
| 08/31/2010 | US7785803 Antibody diagnostic kits and methods of use |
| 08/31/2010 | US7785801 Identification of surface-associated antigens for tumor diagnosis and therapy |
| 08/31/2010 | US7785799 Using immobilized envelope protein domain as tools to identify immunoglobulins generate in response to tick borne encephalitis viral and/or west nile viral infections |
| 08/31/2010 | US7785635 treating urinary tract infections, kidney stones in cats |
| 08/31/2010 | US7785611 comprising a liquid solution consisting of an immunogenic substance and magnesium carbonate hydroxide pentahydrate, used for generating an immune response |
| 08/31/2010 | US7785609 Recombinant Haemophilus influenzae adhesin proteins |
| 08/31/2010 | US7785608 Immunogenic compositions for the prevention and treatment of meningococcal disease |
| 08/31/2010 | US7785607 rapid immune assay based on evaluation of frequency of Interferon (IFN) gamma-producing antigen-specific T lymphocytes responding to selected peptide sequences from Mycobacterium tuberculosis, selected for their immunogenicity; discriminates between latent tuberculosis infection or active infection |
| 08/31/2010 | US7785606 Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
| 08/31/2010 | US7785605 Herpes simplex virus mutant ICP0 protein |
| 08/31/2010 | US7785604 nine residue peptides (ApoptoM) from flavivirus M ectodomain able to modulate specifically the apoptotic activity of diverse flavivirus; use for the treatment and/or the prevention of flavivirus-linked infections and cancers |
| 08/31/2010 | US7785603 Polynucleotide comprising a first nucleic acid fragment which encodes at least 20 contiguous amino acids of an influenza virus polypeptide, wherein codons of nucleic acid fragment are optimized for expression in humans; enhancing immune response of vertebrate in need of protection against IV infection |